hotspot -WSS

hotspot

author：leisure time 2025-09-30 01:02:04 - browse：3

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： 15 die by electrocution after transformer explodes in northern India

leisure time

WSS

More hospitals are billing patients as online messages surge

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Editas, Vertex strike deal on CRISPR

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Violet CEO on training clinicians to promote more inclusive care

Biden administration sends mixed signals on US soldier who crossed into North Korea

focus

hotspot

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bristol Myers buys into radiopharmaceuticals with RayzeBio

After affirmative action ruling, medical educators look to 'holistic review'

Flagship, Pfizer team up in deal worth up to $7 billion

Supreme Court strikes down use of affirmative action

David Ricks of Eli Lilly: best biopharma CEO of 2023

Peter Hotez and the public health issue of online harassment

US soldier in North Korean custody after crossing DMZ line

Supreme Court strikes down use of affirmative action

Twill hunts for pharma partner to market its depression app

hotspot

A look at other Americans who have crossed into North Korea over the years

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

David Ricks of Eli Lilly: best biopharma CEO of 2023

BridgeBio heart drug succeeds in pivotal study

knowledge

explore

leisure time

knowledge